


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Previously Presented) Compounds of the formula I



in which

R¹ and R² are each, independently of one another, H, OH, OR⁸, -SR⁸, -SOR⁸, -SO₂R⁸ or Hal,

R¹ and R² together are alternatively -OCH₂O- or -OCH₂CH₂O-,

R³ and R^{3'} are each, independently of one another, H, A^{R7}, COA^{R7}, COOA^{R7}, CONH₂, CONHA^{R7}, CON(A^{R7})(A^{R7}), CONR¹⁰Het, NH₂, NHA^{R7}, N(A^{R7})(A^{R7}), NCOA^{R7} or NCOOA^{R7},

V and W are oxygen or two hydrogen substituents, with the proviso that, if V is O, W is H,H,

and vice versa,

B is an aromatic isocyclic or heterocyclic radical, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by R⁴, R⁵ and/or R⁶,

X is N or CR³,


R⁴, R⁵

and R⁶ are each, independently of one another, H, A^{R7}, OH, OA^{R7}, NO₂, NH₂,

NHA^{R7}, N(A^{R7})(A^{R7}), NHCOA^{R7}, NHCOOA^{R7}, NHCONH₂,

NHCONHA^{R7}, NHCON(A^{R7})(A^{R7}), Hal, COOH, COOA^{R7}, CONH₂,

CONHA^{R7}, CON(A^{R7})(A^{R7}),



R^7 is H, COOH, COOA, CONH_2 , CONHA, CONAA', NH_2 , NHA, NAA', NCOA, NCOOA, OH or OA,

R^8 is A, cycloalkyl having 3-7 carbon atoms, alkylencycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms,

R^9 is alkyl having 1-10 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylencycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2 , NH, NMe, NEt and/or by —CH=CH— groups, and/or 1-7 H atoms may be replaced by F and/or Cl,

Y is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2 , NH or NR^9 and/or 1-7 H atoms may be replaced by F and/or Cl,

A and A' are each, independently of one another, alkyl having 1-10 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2 , NH or NR^9 and/or 1-7 H atoms may be replaced by F and/or Cl, or aryl or Het,

A and A' together are alternatively an alkylene chain having 2-7 carbon

atoms, in which one, two or three CH₂ groups may be replaced by O, S, SO,
SO₂, NH, NR⁹, NCOR⁹ or NCOOR⁹,

A" and A'" are each, independently of one another,
a bond, alkylene having 1-10 carbon atoms, alkenylene having 2-8 carbon
atoms or cycloalkylene having 3-7 carbon atoms,
in which one, two or three CH₂ groups may be replaced by O, S, SO, SO₂,
NH or NR⁹ and/or
1-7 H atoms may be replaced by F and/or Cl,

A" and A'" together are alternatively an alkylene chain having 2-7 carbon
atoms, in which one, two or three CH₂ groups may be replaced by O, S, SO,
SO₂, NH, NR⁹, NCOR⁹ or NCOOR⁹,

aryl is phenyl, naphthyl, fluorenyl or biphenyl, each of which is un-
substituted or monosubstituted, disubstituted or trisubstituted by Hal, R¹¹,
OR¹⁰, N(R¹⁰)₂, NO₂, CN, COOR¹⁰, CON(R¹⁰)₂, NR¹⁰COR¹⁰,
NR¹⁰CON(R¹⁰)₂, NR¹⁰SO₂A, COR¹⁰, SO₂N(R¹⁰)₂ or S(O)_mR¹¹,

R¹⁰ is H or alkyl having 1-6 carbon atoms,

R¹¹ is alkyl having 1-6 carbon atoms,

Het is a monocyclic or bicyclic saturated, unsaturated or aromatic
heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be
unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal,
R¹¹, OR¹⁰, N(R¹⁰)₂, NO₂, CN, COOR¹⁰, CON(R¹⁰)₂, NR¹⁰COR¹⁰,
NR¹⁰CON(R¹⁰)₂, NR¹⁰SO₂R¹¹, COR¹⁰, SO₂NR¹⁰ and/or S(O)_mR¹¹,

Hal is F, Cl, Br or I,

m is 0, 1 or 2,

a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all
ratios.

Claim 2. (Previously Presented) Compounds according to Claim 1, in which
R¹ and R² are each, independently of one another, alkoxy having 1, 2, 3, 4, 5 or 6 carbon
atoms,
a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all
ratios.

Claim 3. (Previously Presented) Compounds according to Claim 1, in which R^1 and R^2 are each, independently of one another, H, methoxy, ethoxy, benzyloxy, propoxy, isopropoxy, difluoromethoxy, F, Cl, cyclopentyloxy, cyclohexyloxy or cycloheptyloxy, a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 4. (Previously Presented) Compounds according to Claim 1, in which R^1 and R^2 are each, independently of one another, methoxy, ethoxy, propoxy, isopropoxy, cyclopentyloxy or F, a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 5. (Previously Presented) Compounds according to Claim 1, in which R^1 4-methoxy or 4-ethoxy, R^2 is 3-methoxy, 3-ethoxy, 3-propoxy, 3-isopropoxy or 3-cyclopentyloxy, a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 6. (Previously Presented) Compounds according to Claim 1, in which R^3 is H or $A''R^7$, a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.


Claim 7. (Previously Presented) Compounds according to Claim 1, in which X is N or CH, a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 8. (Previously Presented) Compounds according to Claim 1, in which B is an aromatic isocyclic or monocyclic saturated or unsaturated heterocyclic ring having 1 or 2 N, O and/or S atoms,

a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 9. (Previously Presented) Compounds according to Claim 1, in which
B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolynyl, oxazolynyl, thiazolynyl, pyrazolynyl, imidazolynyl, naph-thyl, quinolynyl, isoquinolynyl, cinnolynyl, phthalazynyl, quinazolynyl or quinoxalynyl, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by R^4 , R^5 and/or R^6 ,
a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 10. (Previously Presented) Compounds according to Claim 1, in which
B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolynyl, oxazolynyl, thiazolynyl, pyrazolynyl, imidazolynyl, naphthyl, quinolynyl, isoquinolynyl, cinnolynyl, phthalazynyl, quinazolynyl or quinoxalynyl, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by OH, OA, NO_2 , NH_2 , NAA',



a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 11. (Previously Presented) Compounds according to Claim 1, in which

B is unsubstituted pyridyl, pyridyl N-oxide, thienyl or pyrazinyl,
a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 12. (Previously Presented) Compounds according to Claim 1, R¹ and R²
are each, independently of one another, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms,

X is N or CH,

R³ is H or A''R⁷,

A'' and A''' are each, independently of one another, absent or alkylene having 1-10 carbon atoms, in which one CH₂ group may be replaced by NH or NR⁹,

A'' and A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one CH₂ group may be replaced by NH or NR⁹,

B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazoliny, oxazoliny, thiazoliny, pyrazoliny, imidazoliny, naphthyl, quinoliny, isoquinoliny, cinnoliny, phthalaziny, quinazoliny or quinoxaliny, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by OH, OA, NO₂, NH₂, NAA',

R⁷ is H, COOH, NHA or NAA',

R⁹ is alkyl having 1-6 carbon atoms,

A and A' are each, independently of one another, alkyl having 1-10 carbon atoms, in which 1-7 H atoms may be replaced by F and/or Cl,
a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 13. (Previously Presented) Compounds according to Claim 1, in which

R¹ is 4-methoxy or 4-ethoxy,


R² is 3-methoxy, 3-ethoxy, 3-propoxy, 3-isopropoxy or 3-cyclopentyloxy,

X is N,

R³ is H or alkyl having 1-6 carbon atoms,

B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl,

pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazoliny, oxazoliny, thiazoliny, pyrazoliny, imidazoliny, naphthyl, quinoliny, isoquinoliny, cinnoliny, phthalazinyl, quinazoliny or quinoxaliny, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by OH, OA, NO₂, NH₂, NAA',



R⁷ is H,
R⁹ is alkyl having 1-6 carbon atoms,
A and A' are each, independently of one another, alkyl having 1-10 carbon atoms, in which 1-7 H atoms may be replaced by F and/or Cl,
a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 14. (Previously Presented) Compounds according to Claim 1, in which

R¹ is 4-methoxy or 4-ethoxy,
R² is 3-methoxy, 3-ethoxy, 3-propoxy, 3-isopropoxy or 3-cyclopentyloxy,

x is N,

R³ is H or alkyl having 1-6 carbon atoms,

V is H,H,

W is O,

B is unsubstituted pyridyl, pyridyl N-oxide, thienyl or pyrazinyl,

a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all

ratios.

Claim 15. (Previously Presented) Compounds according to Claim 1, in which

R¹ is 4-methoxy or 4-ethoxy,

R² is 3-methoxy, 3-ethoxy, 3-propoxy, 3-isopropoxy or 3-cyclopentyloxy,


X is N,

R³ is H or alkyl having 1-6 carbon atoms,

V is H,H,

W is O,

B is unsubstituted pyridyl, pyridyl N-oxide, thienyl or pyrazinyl or phenyl, which is unsubstituted or may be monosubstituted by OH, OA, NO₂, NH₂, NAA',



A and A' are each, independently of one another, alkyl having 1-10 carbon atoms, in which 1-7 H atoms may be replaced by F and/or Cl, a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 16. (Previously Presented) Compounds of the formula I according to Claim 1 from the group consisting of

- a) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypridin-2-yl)thiazol-5-yl]methanone,

- b) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone,
- c) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone,
- d) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-3-ylthiazol-5-yl)methanone,
- e) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-(4-methyl-2-pyridin-3-ylthiazol-5-yl)methanone,
- f) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-3-ylthiazol-5-yl)methanone,
- g) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-2-ylthiazol-5-yl)methanone,
- h) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-2-ylthiazol-5-yl)methanone,
- i) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyridin-2-ylthiazol-5-yl)methanone,
- j) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-(4-methyl-2-pyrazin-2-ylthiazol-5-yl)methanone,
- k) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyrazin-2-ylthiazol-5-yl)methanone,
- l) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-pyrazin-2-ylthiazol-5-yl)methanone,
- m) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-thiophen-2-ylthiazol-5-yl)methanone,
- n) 1-[3-(3-isopropoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-thiophen-2-ylthiazol-5-yl)methanone,
- o) 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-(4-methyl-2-thiophen-2-ylthiazol-5-yl)methanone,
- p) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-phenylthiazol-5-yl]methanone,
- q) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(4-methoxyphenyl)thiazol-5-yl]methanone,
- r) 1-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-

2-(4-aminophenyl)thiazol-5-yl]methanone,

s) 2-[(4-{5-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-carbonyl]-4-methylthiazol-2-yl}phenyl)hydrazono]malononitrile,

t) 2-[(4-{5-[3-(3-ethoxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-carbonyl]-4-methylthiazol-2-yl}phenyl)hydrazono]-2-(1*H*-tetrazol-5-yl)acetonitrile,

a pharmaceutically acceptable salt or stereoisomers thereof, or a mixture thereof in all ratios.

Claim 17. (Canceled)

Claim 18. (Canceled)

Claim 19. (Previously Presented) Medicament comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable salt or stereoisomers thereof, including mixtures thereof in all ratios, and, optionally, excipients and/or adjuvants.

Claim 20. (Canceled)

Claim 21. (Previously Presented) A method for treating asthma, comprising administering to a host in need thereof, an effective amount of a compound according to Claim 1.

Claim 22. (Canceled)

Claim 23. (Canceled)

Claim 24. (Canceled)

Claim 25. (Canceled)

Claim 26. (Canceled)

Claim 27. (Canceled)

Claim 28. (Canceled)

Claim 29. (Canceled)

Claim 30. (Canceled)

Claim 31. (Previously Presented) A method of inhibiting proliferation of T-cells in a host in need thereof, comprising administering to said host an effective amount of a compound of claim 1.

Claim 32. (Previously Presented) A method of inhibiting cytokine production in human peripheral blood monocytes in a host in need thereof, comprising administering to said host an effective amount of a compound of claim 1.